Ibio To Participate In The 2026 Wells Fargo Annual Healthcare Conference
Martin Brenner, DVM, Ph.D., Chief Executive Officer and Chief Scientific Officer of iBio, will participate in a fireside chat on Tuesday, September 8, at 4:30 p.m. ET.
A livestream of the event can be accessed here, and a replay of the presentation webcast will be available on the Investor Relations section of the iBio website for 90 days following the event.
Felipe Duran, iBio's Chief Financial Officer, will be available with Dr. Brenner for one-on-one investor meetings during the conference. To request a meeting with Dr. Brenner or Mr. Duran at either conference, please contact ....
About iBio, Inc.
iBio (Nasdaq: IBIO) is a clinical-stage biotechnology developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, cancer, and other hard-to-treat diseases. Combining advanced antibody engineering with AI-driven discovery, iBio is advancing a differentiated pipeline designed to deliver sustained therapeutic effects and address significant unmet medical needs. iBio's mission is to transform drug discovery, accelerate development timelines, and unlock new possibilities in precision medicine.
For more information, visit or follow us on LinkedIn.
Contact:
iBio, Inc.
Investor Relations
...
Ignacio Guerrero-Ros, Ph.D., or David Schull
Russo Partners, LLC
...
...
(858) 717-2310 or (646) 942-5604
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment